Wedbush @Wedbush · 19 Aug 2026
Equity Research Analyst, David Nierengarten, Ph.D. initiated on Aktis Oncology ($AKTS) at #OUTPERFORM ($35 PT). AKTS is developing targeted cancer therapies that deliver a radioactive payload directly to tumor cells, killing them from within while sparing healthy tissue. Two https://t.co/cUj0hFIaor
428Views
0Likes
0Reposts
0Replies
0Quotes
0Bookmarks
Is that a lot?
0.84×vs this author's median509 views is typical
20Percentile for this authorof 5 recent posts
0.14×vs 10K–100K median3 137 views is typical
3.63%Reachviews ÷ followers
0.00%Engagement rateof viewers reacted